Ind-Swift Laboratories Limited (INDSWFTLAB) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Ind-Swift Laboratories Limited stock ₹67.73, price ₹361, that is 81.3% below the price, quality 29 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Ind-Swift Laboratories Limited
INDSWFTLAB · NSEFar too expensive (fair value 81% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range ₹53.40 – ₹413.10 · fair‑value band ₹57.15 – ₹84.66 · the ₹361.30 price screens above the ₹67.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Every Wednesday you see whether Ind-Swift Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally.
Show moreShow less
The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia.
It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services.
The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Stock analysis
Ind-Swift Laboratories Limited (INDSWFTLAB) currently trades at ₹361.30, while our model-based Fair Value estimate is ₹67.73, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹77.80 per share, and 2 of the 15 models we run sit above the ₹361.30 price.
Bear case: the Earnings-Based group reads lowest at ₹45.58, and 13 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹57.15 (bear) to ₹84.66 (bull), the price of ₹361.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Ind-Swift Laboratories Limited reported revenue of ₹6.4B in FY2026 versus ₹10.4B in FY2022, a compound −11.4%/yr. Reported net income was ₹414M in FY2026.
Key figures
Market cap ₹30.9B (≈ $328M) Small · P/E ratio 54.0 · P/S ratio 4.58 · EPS (TTM) ₹6.69 · Net margin 8.5% · Return on equity 3.2% · Return on assets (EBIT) 5.3% (5-year average) · Operating margin 13.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 13% below its 52-week high and 310% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −81%, INDSWFTLAB screens richer than that median.
Fair Value models
All 15 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
INDSWFTLAB screens overvalued: fair value 81% below the price. Compare with Merck KGaA →
Compare Ind-Swift Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs INDSWFTLAB |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs INDSWFTLAB |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs INDSWFTLAB |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs INDSWFTLAB |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs INDSWFTLAB |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs INDSWFTLAB |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs INDSWFTLAB |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs INDSWFTLAB |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs INDSWFTLAB |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs INDSWFTLAB |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ind-Swift Laboratories Limited (INDSWFTLAB) overvalued or undervalued?
What is the fair value of INDSWFTLAB?
What is the quality score of INDSWFTLAB?
What is the price target for Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the Ind-Swift Laboratories Limited stock forecast for 2026?
What is the revenue of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the intrinsic value of Ind-Swift Laboratories Limited (INDSWFTLAB)?
Is Ind-Swift Laboratories Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of INDSWFTLAB?
How much is Ind-Swift Laboratories Limited worth?
What do the bullish and bearish scenarios say about INDSWFTLAB?
What is the P/E ratio of INDSWFTLAB?
How solid is the balance sheet of Ind-Swift Laboratories Limited (INDSWFTLAB)?
How far is INDSWFTLAB from its 52-week high?
Which stocks are comparable to Ind-Swift Laboratories Limited?
Is Ind-Swift Laboratories Limited stock attractive at the current price?
How is the fair value of INDSWFTLAB calculated?
Is it still worth investing in stocks now?
What is the share price of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What should I pay attention to with Ind-Swift Laboratories Limited right now?
Key figures of Ind-Swift Laboratories Limited
How large is the market capitalisation of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the P/S ratio of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What are the earnings per share of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the net margin of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the return on equity of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the EBIT return on assets of Ind-Swift Laboratories Limited (INDSWFTLAB)?
What is the operating margin of Ind-Swift Laboratories Limited (INDSWFTLAB)?
How fast is revenue growing at Ind-Swift Laboratories Limited (INDSWFTLAB)?
How fast are earnings growing at Ind-Swift Laboratories Limited (INDSWFTLAB)?
How much free cash flow does Ind-Swift Laboratories Limited (INDSWFTLAB) generate?
How much net cash does Ind-Swift Laboratories Limited (INDSWFTLAB) hold?
Watch Ind-Swift Laboratories Limited in the live analysis
One click puts Ind-Swift Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.